A line of evidences has demonstrated that a normalization of blood glucose can prevent or delay diabetic complications. To normalize blood glucose in diabetic patients who require insulin treatment, a tailoring the time-action profile of injected insulin is needed. B29Lys-myristoyl. des-B30 human insulin(NN-304), which metabolic action is prolonged by association of the fatty acid residue to albumin in the blood and peripheral tissues, belongs to a new class of soluble long-acting insulin analogs. The aim of clinical development of NN-304 is to reduce the disadvantages of currently available long-acting insulin formulations. NN-304 might offer advantages in clinical use such as reproducing physiological basal insulin action derived from a flatter time-action profile.